These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34958505)

  • 1. Evolving classification of rhabdomyosarcoma.
    Agaram NP
    Histopathology; 2022 Jan; 80(1):98-108. PubMed ID: 34958505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Myogenic Sarcomas.
    Agaram NP
    Surg Pathol Clin; 2019 Mar; 12(1):51-62. PubMed ID: 30709448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry.
    Dehner CA; Rudzinski ER; Davis JL
    Hum Pathol; 2024 May; 147():72-81. PubMed ID: 38135061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerosing rhabdomyosarcoma in childhood: case report and review of the literature.
    Vadgama B; Sebire NJ; Malone M; Ramsay AD
    Pediatr Dev Pathol; 2004; 7(4):391-6. PubMed ID: 15383934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current landscape of rhabdomyosarcomas: an update.
    Leiner J; Le Loarer F
    Virchows Arch; 2020 Jan; 476(1):97-108. PubMed ID: 31696361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
    Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
    Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues].
    Mentzel T
    Pathologe; 2010 Mar; 31(2):91-6. PubMed ID: 19997735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
    Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J
    Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcoma: From Obscurity to Clarity in Diagnosis … But With Ongoing Challenges in Management: The Farber-Landing Lecture of 2020.
    Parham DM; Giannikopoulos P
    Pediatr Dev Pathol; 2021; 24(2):87-95. PubMed ID: 33439112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.
    Parham DM
    Mod Pathol; 2001 May; 14(5):506-14. PubMed ID: 11353062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcomas.
    Wesche WA; Fletcher CD; Dias P; Houghton PJ; Parham DM
    Am J Surg Pathol; 1995 Mar; 19(3):261-9. PubMed ID: 7872424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma.
    Fan R; Parham DM; Wang LL
    Arch Pathol Lab Med; 2022 Aug; 146(8):953-959. PubMed ID: 35051261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
    Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
    Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of FOXO1 immunohistochemistry for rhabdomyosarcoma classification.
    Rutland CD; Gedallovich J; Wang A; Zdravkovic S; Varma S; Hornick JL; Charville GW
    Histopathology; 2023 Jul; 83(1):49-56. PubMed ID: 36860202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
    Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
    Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.